Moreover, it has been found that TrxR1 inactivation by chemical inhibitors may reverse tumor growth and sensitize cancer cells to chemotherapeutic drugs, suggesting that TrxR1 may serve as an attractive therapeutic target for anticancer drug development [14–17]. This evidence concerns the gene TXNRD1 and neoplasm.